Literature DB >> 32106864

Undiagnosed HIV, hepatitis B, and hepatitis C infections in people with severe psychiatric disorders in Ethiopia.

Getinet Ayano1,2, Kibrom Haile3, Abel Tesfaye3,4, Kelemua Haile3, Sileshi Demelash5, Mikias Tulu3, Belachew Tsegaye3, Melat Solomon3, Alem Kebede3, Aynalem Biru3, Habte Birhanu3, Gebresilassie Zenawi3, Yodit Habtamu3, Esias Kibron3, Seneshet Eshetu3, Meseret Sefiw3, Dawit Assefa3, Zegeye Yohannes3.   

Abstract

BACKGROUND: Worldwide, there is limited epidemiologic evidence on the seroprevalence of undiagnosed chronic viral infections including HIV, hepatitis B virus (HBV) and hepatitis C virus (HCV) infections among patients with severe psychiatric disorders. To our knowledge, this is the first study to explore and compare undiagnosed seroprevalence rates of HIV, HBV, and HCV infections among patients with severe psychiatric disorders.
METHOD: In this study, we included a random sample of 309 patients with severe psychiatric disorders selected by systematic sampling technique. We used a structured clinical interview for DSM-IV (SCID) to confirm the diagnosis of severe psychiatric disorders among the participants. Binary and multivariable logistic regression models, adjusting for the potential confounding factors was used to explore the potential determinants of chronic viral infections. RESULT: The prevalence estimates of HIV infection among patients with severe psychiatric disorders in this study (3.24%) was roughly 3 times the estimated population prevalence of HIV infection in Ethiopia (1.1%). This study showed that the prevalence rates of HBV and HCV infections among patients with severe psychiatric disorders were 4.85 and 1.29%, respectively. Our results also showed that among patients with chronic viral infections, HIV, HBV and HCV, 76.92, 60, 80, and 75% respectively were undiagnosed. Regarding associated factors, the presence of chronic viral infection was found to be significantly associated with the age of the participants (ranging between 30 and 40 years) after adjusting for the possible confounding factors [AOR = 3.95 (95%CI.18-13.17)].
CONCLUSION: Even though the prevalence estimates of HIV (3.24%), HBV (4.85%), and HCV (1.29%) infections were high among patients with severe psychiatric disorders, the majority of them remained undiagnosed. HBV was found to be the commonly undiagnosed infection (4 out of 5) followed by HCV (3 out of 4) and HIV (6 out of 10). The present study provided evidence of a significant association between the age of the participant (between 30 and 40 years) and chronic viral infections in patients with severe psychiatric disorders. Increasing the awareness of psychiatry professionals and early screening, as well as interventions of chronic viral infections among patients with severe psychiatric disorders are imperative.

Entities:  

Keywords:  And HCV infection; HBV infection; HIV infection; Severe psychiatric disorder; Undiagnosed

Year:  2020        PMID: 32106864     DOI: 10.1186/s12879-020-4907-1

Source DB:  PubMed          Journal:  BMC Infect Dis        ISSN: 1471-2334            Impact factor:   3.090


  3 in total

1.  Seroprevalence of Hepatitis C Viral Infection in Ethiopia: A Systematic Review and Meta-Analysis.

Authors:  Teshiwal Deress; Yihenew Million; Teshome Belachew; Mohabaw Jemal; Mekonnen Girma
Journal:  ScientificWorldJournal       Date:  2021-04-09

2.  Study protocol: a randomised, controlled trial of a nurse navigator program for the management of hepatitis C virus in patients with severe mental disorder.

Authors:  Casta Quemada-González; José Miguel Morales-Asencio; María M Hurtado; Celia Martí-García
Journal:  BMC Nurs       Date:  2022-04-20

3.  Prevalence and correlates of diagnosed and undiagnosed epilepsy and migraine headache among people with severe psychiatric disorders in Ethiopia.

Authors:  Getinet Ayano; Sileshi Demelash; Zegeye Yohannes; Kibrom Haile; Light Tsegay; Abel Tesfaye; Kelemua Haile; Mikias Tulu; Belachew Tsegaye; Melat Solomon; Getahun Hibdye; Dawit Assefa; Berihun Assefa Dachew
Journal:  PLoS One       Date:  2020-11-20       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.